相似文献
1
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Annu Rev Med. 2015;66:509-23. doi: 10.1146/annurev-med-053013-062946. Epub 2014 Oct 17.
2
NMDA antagonist treatment of depression.
Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11.
3
Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Neuropharmacology. 2016 Jan;100:17-26. doi: 10.1016/j.neuropharm.2015.07.028. Epub 2015 Jul 26.
4
Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Transl Psychiatry. 2016 Sep 20;6(9):e894. doi: 10.1038/tp.2016.145.
5
Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Behav Brain Res. 2020 Apr 20;384:112548. doi: 10.1016/j.bbr.2020.112548. Epub 2020 Feb 13.
6
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
7
Ketamine for Treatment-Resistant Depression: a New Advocate.
Rev Invest Clin. 2018;70(2):65-7. doi: 10.24875/RIC.18002501.
8
Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
Brain Behav. 2019 Nov;9(11):e01423. doi: 10.1002/brb3.1423. Epub 2019 Oct 15.
9
The role of mTOR in depression and antidepressant responses.
Life Sci. 2014 Apr 17;101(1-2):10-4. doi: 10.1016/j.lfs.2014.02.014. Epub 2014 Feb 25.
10
Ketamine for Major Depressive Disorder.
Curr Top Behav Neurosci. 2024;66:131-147. doi: 10.1007/7854_2023_453.
引用本文的文献
1
The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment.
Int J Mol Sci. 2025 Jul 11;26(14):6673. doi: 10.3390/ijms26146673.
2
Effect of low-dose esketamine on postoperative quality of recovery in total laparoscopic hysterectomy: a randomized controlled trial.
Perioper Med (Lond). 2025 Jul 23;14(1):78. doi: 10.1186/s13741-025-00567-z.
3
Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.
Int J Neuropsychopharmacol. 2025 Jun 6;28(6). doi: 10.1093/ijnp/pyaf037.
4
Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats.
Transl Psychiatry. 2025 Feb 17;15(1):54. doi: 10.1038/s41398-025-03277-8.
5
Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.
BMC Psychiatry. 2025 Jan 7;25(1):23. doi: 10.1186/s12888-024-06448-x.
6
Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression.
Pharmaceuticals (Basel). 2024 Dec 4;17(12):1627. doi: 10.3390/ph17121627.
7
Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.
Biomedicines. 2024 Nov 29;12(12):2744. doi: 10.3390/biomedicines12122744.
8
The neural basis of neuropsychiatric symptoms in Alzheimer's disease.
Front Aging Neurosci. 2024 Dec 5;16:1487875. doi: 10.3389/fnagi.2024.1487875. eCollection 2024.
9
Elevated neuron specific enolase levels in post-traumatic stress disorder.
Eur J Pediatr. 2024 Nov 25;184(1):41. doi: 10.1007/s00431-024-05889-6.
10
Mechanisms of Differential Sensitivity to Ethanol-Induced Apoptosis in Mouse Spinal Cord at Different Developmental Stages-Akt/GSK Signaling and BAX.
Mol Neurobiol. 2025 Apr;62(4):4301-4318. doi: 10.1007/s12035-024-04510-z. Epub 2024 Oct 23.
本文引用的文献
1
A randomized controlled trial of intranasal ketamine in major depressive disorder.
Biol Psychiatry. 2014 Dec 15;76(12):970-6. doi: 10.1016/j.biopsych.2014.03.026. Epub 2014 Apr 3.
2
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
JAMA Psychiatry. 2014 Jun;71(6):681-8. doi: 10.1001/jamapsychiatry.2014.62.
3
REDD1 is essential for stress-induced synaptic loss and depressive behavior.
Nat Med. 2014 May;20(5):531-5. doi: 10.1038/nm.3513. Epub 2014 Apr 13.
4
Acute antidepressant effects of intramuscular versus intravenous ketamine.
Indian J Psychol Med. 2014 Jan;36(1):71-6. doi: 10.4103/0253-7176.127258.
5
Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
J Psychopharmacol. 2014 Jun;28(6):536-44. doi: 10.1177/0269881114527361. Epub 2014 Apr 3.
6
Do the dissociative side effects of ketamine mediate its antidepressant effects?
J Affect Disord. 2014 Apr;159:56-61. doi: 10.1016/j.jad.2014.02.017. Epub 2014 Feb 18.
7
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
Depress Anxiety. 2014 Apr;31(4):335-43. doi: 10.1002/da.22253. Epub 2014 Mar 25.
8
Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950.
9
Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
J Affect Disord. 2014 Feb;155:123-9. doi: 10.1016/j.jad.2013.10.036. Epub 2013 Oct 29.
10
Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
Int J Neuropsychopharmacol. 2014 Feb;17(2):331-6. doi: 10.1017/S1461145713001119. Epub 2013 Oct 8.
Zotero 插件